论文部分内容阅读
干扰素(IFN)在病毒性肝炎中的作用至今仍在探讨,有一些晚近的研究表明,血清IFN在一些甲型肝炎病人或被HAV感染的实验黑猩猩中得以证实。病人和方法:将127例急性甲型肝炎患者血清(HAV抗体IgM阳性)置于-20℃下待验,所有的血清是在疾病的急性期即临床症状出现10天内收集,120个健康人作对照,不检测乙型肝炎或非甲非乙型肝炎患者。确定抗病毒活性是在血清连续双倍稀释中测量小疱口炎病毒对牛肾细胞致病效应的抑制,抗病毒单位以抑制50％细胞致病效应最高稀释度的倒数计算,1单位与世界卫生组织人白细胞相关干扰素B69/19参照单位大致相等,本试验探知的低限为5Iu/ml。结果:与无可测知血清IFN浓度的健康对照组不同,127例中40例急性甲型肝炎患者血
The role of interferon (IFN) in viral hepatitis is still being explored to date and some recent studies have shown that serum IFN is confirmed in some Hepatitis A patients or experimental chimpanzees infected with HAV. PATIENTS AND METHODS: Serum (HAV IgM positive) from 127 patients with acute hepatitis A was tested at -20 ° C. All sera were collected within 10 days of the onset of clinical symptoms in the acute phase of the disease. 120 healthy individuals Control, no detection of hepatitis B or non-A non-hepatitis B patients. The antiviral activity was determined by measuring the inhibition of pathogenic effects of vesicular stomatitis virus on bovine renal cells in a serial double-titer dilution of serum. Antiviral units were calculated as the reciprocal of the highest dilution that inhibits pathogenic effects by 50% WHO human leukocyte associated interferon B69 / 19 reference units roughly equal, the test to find the lower limit of 5Iu / ml. RESULTS: In contrast to the healthy control group with no measurable serum IFN concentrations, 40 of the 127 patients with acute hepatitis A